Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Invests In Its Unique Antibiotics Offering

CEO Richard Saynor Outlines The Attraction Of Recently-Closed Deal With GSK

Executive Summary

In the wake of a major deal to acquire GlaxoSmithKline’s cephalosporins business, Sandoz CEO Richard Saynor has set out why the company’s unique position means that antibiotics are an important area for investments, in an exclusive interview with Generics Bulletin.

You may also be interested in...



European Industry Demands Action To Sustain Health Systems

Industry actors and outsiders alike discussed existing challenges for the EU healthcare system amid significant economic pressures, while calling for action to ensure a workable system for low-priced medicines.

AMR Industry Alliance Publishes Manufacturing Standard

The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.

AMR Industry Alliance Publishes Manufacturing Standard

The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel